Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
260 | UPDATED ANALYSIS OF A PHASE 2 MULTICENTER STUDY OF THE LONCASTUXIMAB IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA DEMONSTRATES HIGH RATE OF COMPLETE RESPONSES
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study
Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group
Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation